The novel PI3K-δ inhibitor TGR-1202 enhances Brentuximab Vedotin-induced Hodgkin lymphoma cell death via mitotic arrest.
Locatelli SL
Leukemia. 2016 Aug 8;30(12):2402-2405. doi: 10.1038/leu.2016.224
Bendamustine in Combination With Gemcitabine and Vinorelbine Is an Effective Regimen As Induction Chemotherapy Before Autologous Stem-Cell Transplantation for Relapsed or Refractory Hodgkin Lymphoma: Final Results of a Multicenter Phase II Study.
Santoro A
J Clin Oncol. 2016 Jul 5;34(27):3293-9. doi: 10.1200/JCO.2016.66.4466
The patient’s CMV serological status affects clinical outcome after T-cell replete haplo-HSCT and post-transplant cyclophosphamide.
Crocchiolo R
Bone Marrow Transplant. 2016 Mar 21;51(8):1134-6. doi: 10.1038/bmt.2016.69
Desensitization with plasma exchange in a patient with human leukocyte antigen donor-specific antibodies before T-cell-replete haploidentical transplantation.
Bramanti S
Transfusion. 2016 Mar 28;56(5):1096-1100. doi: 10.1111/trf.13523
Tacrolimus compared with cyclosporine A after haploidentical T-cell replete transplantation with post-infusion cyclophosphamide.
Castagna L
Bone Marrow Transplant. 51(3):470. doi: 10.1038/bmt.2015.327
T-replete haploidentical allogeneic transplantation using post-transplantation cyclophosphamide in advanced AML and myelodysplastic syndromes.
Devillier R
Bone Marrow Transplant. 2015 Nov 9;51(2):194-8. doi: 10.1038/bmt.2015.270
Tandem autologous-allogeneic stem cell transplantation as a feasible and effective procedure in high-risk lymphoma patients.
Crocchiolo R
Haematologica. 2015 Jul 23;100(10):e423-7. doi: 10.3324/haematol.2015.129452
Brentuximab vedotin in patients with Hodgkin lymphoma and a failed allogeneic stem cell transplantation: results from a named patient program at four Italian centers.
Carlo-Stella C
Oncologist. 2015 Feb 10;20(3):323-8. doi: 10.1634/theoncologist.2014-0420
Infections after T-replete haploidentical transplantation and high-dose cyclophosphamide as graft-versus-host disease prophylaxis.
Crocchiolo R
Transpl Infect Dis. 17(2):242-9. doi: 10.1111/tid.12365
High-dose melphalan with autologous stem cell support in refractory Hodgkin lymphoma patients as a bridge to second transplant.
Castagna L
Bone Marrow Transplant. 2015 Jan 26;50(4):499-504. doi: 10.1038/bmt.2014.304